Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RGNX vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Captures Overall Composite Edge (36.8 SELL vs 39.4 SELL), While RGNX Leads 4–2 on Growth & Valuation Pillars

BOLD Overall Winner 6-Pillar Tally: RGNX 4 – 2 BOLD Matrix Metrics: RGNX 2 – 6 BOLD

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (36.8/100 SELL vs. 39.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.16 (N/M Forward P/E, -120.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (39.4/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY).
  • Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both RGNX (39.4/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: RGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs BOLD
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.16
-0.28% 1D
Market Cap $474.8M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.65β · 74% Vol
Unified Composite Score
39.4 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.7%), weak momentum, RSI 45
RSI-14: 44.8 · SMA20: $7.43 · SMA50: $7.51
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (RGNX 4 – 2 BOLD)

Columns: Metric · RGNX · BOLD
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 2.9x N/M
2. Growth & Scale RGNX
Revenue Growth (YoY) -69.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M N/A
Market Cap $474.8M $56.2M
3. Profitability & Quality BOLD
Gross Margin -64.5% N/A
Operating Margin -120.4% 0.0%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -64.6%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$48M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 502.0% (53rd %ile) N/A (N/A)
Put/Call OI Skew 0.14x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (2) vs BOLD (6)
Institutional Metric RGNX BOLD Criterion Row Edge
Market Capitalization
Scale
$474.8M $56.2M Larger Scale RGNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% +0.0% Higher Growth BOLD
Operating Margin (TTM)
Profitability
-120.4% 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-113.2% -64.6% Higher ROE BOLD
52-Week Range Position
Momentum
16% ($5–$16) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
1.65β · 74% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
39.4 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 2.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +4.78 pp
RGNX: -0.14% · BOLD: -4.92%
3M Horizon RGNX +10.51 pp
RGNX: -11.11% · BOLD: -21.62%
6M Horizon BOLD +48.35 pp
RGNX: +12.76% · BOLD: +61.11%
1Y Horizon BOLD +136.23 pp
RGNX: -34.49% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RGNX vs BOLD. Trailing 12-month operating profitability (RGNX -120.4% vs BOLD 0.0%) and valuation multiples (RGNX N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RGNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$154M
Gross Margin-64.5%
Op. Margin-120.4%
ROE / Fwd P/E-113.2% · N/M
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 502.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $474.8M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (36.8/100 SELL vs. 39.4/100 SELL) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.16 (N/M Forward P/E, -120.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (39.4/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both RGNX (39.4/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: RGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RGNX leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RGNX generates $154M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 2.9x EV/Revenue (-100.6% FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 502.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 74% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.